Table 2.

Characteristics of patients vaccinated in Phase I and Phase II studies.

N	Sex	Age	Primary CM	N	AJCC stage	Clinical Study	DMFS	OS	Treatments post DM
1	M	42	T4b	N2b	IIIC	CASVAC	2	12	QT
2	M	52	T2a	N2b	IIIB	CASVAC	150+	150	0
3	F	33	T4b	N0	IIC	CASVAC	34	47	V
4	F	41	T3b	N2b	III C	CASVAC	141+	141+	0
5	F	33	T1b	N1c	IIIB	CASVAC	136+	136+	V, HP, N, D/TRA
6	M	61	T0	N2b	IIIC	CASVAC	137+	137+	0
7	M	48	T4b	N1a	III C	CASVAC	94	120	RT; N; D/Tra
8	M	50	T3a	N1a	III B	CASVAC	130+	130+	0
9	F	51	T3a	N1a	IIIB	CASVAC	25	79	V
10	F	39	T2a	N2a	IIIB	CASVAC	12	30	V
11	M	47	T3a	N1a	III B	CASVAC	107+	107+	0
12	M	46	T3B	N2A	IIIC	CASVAC	57	89+	U
13	M	35	T3a	N1a	III B	CASVAC	101+	101+	0
14	M	40	T3b	N3	IIIC	CASVAC	10	14	RT; V
15	F	51	T4b	N1a	IIIC	CASVAC	97+	97+	0
16	M	35	T3b	N1b	IIIC	CASVAC	7	14	0
17	F	61	T4a	N0	IIB	CASVAC	36	77+	U
18	F	43	T2a	N2c	IIIC	CASVAC	91+	91+	0
19	M	46	T4b	N0	IIC	CASVAC	44	91+	N
20	F	49	T?	N1	IIIA	VACCIMEL	216+	216+	0
21	M	33	T2	N0	IIB	VACCIMEL	52	90	U
22	F	45	T2a	N0	IIB	VACCIMEL	204+	204+	0
23	F	33	T0	N3b	IIIC	VACCIMEL	112	132	I
24	F	15	T4a	N2b	IIIC	VACCIMEL	218+	218+	0
25	F	56	T0	N2b	IIIC	VACCIMEL	213+	213+	0
26	F	32	T2b	N1b	IIIB	VACCIMEL	223+	223+	0
27	F	48	T0	N2b	IIIC	VACCIMEL	218+	218+	0
28	M	28	T2b	N1c	IIIC	VACCIMEL	3	28	QT
29	M	65	T4a	N1c	IIIC	VACCIMEL	156	156	U
30	F	65	T4a	N1c	IIIC	VACCIMEL	10	23	QT

Clinical stages were determined according to 8th edition AJCC. DMFS, distant metastasis-free survival; OS, overall survival; DM, distant metastases; 0, no treatment; HT, hyperthermic perfusion; QT, chemotherapy; V, vemurafenib; I, ipilimumab; RT, radiotherapy; N, nivolumab; D/Tra, dabrafenib/trametinib; U, unknown.